Key facts
- Phantom Neuro’s last known valuation is $52.0M (Aug 2025).
- It has raised $28.5M across 2 recorded rounds; the latest was Early Stage VC ($12.1M) in Mar 2025.
- Notable investors include Gaingels, Capital Factory, Draper Associates, Crosscourt Ventures, Rsquared — 20 tracked in total.
- Phantom Neuro has filed 2 Form Ds with the SEC since 2022, most recently Mar 2025 ($12.1M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Phantom Neuro
Funding rounds
2 roundsAbout Phantom Neuro
Operator of a neurotechnology company intended to bridge the gap between modern-day robotics and individuals with limb differences. The company's machine control system maximizes the potential of robotic orthopedics in real-world environments by leveraging neuroscience and artificial intelligence, enabling patients with limb deficits to regain control over their lives.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2020
- Employees
- 19
- Website
- phantomneuro.com/
- Ownership
- Privately Held (backing)
Phantom Neuro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phantom Neuro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phantom Neuro in its N-PORT filings yet. We sweep new filings monthly.